<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Chemotherapeutic Agents: Antimycobacterials, Antifungals, and Antivirals</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="pharmacology-chemotherapeutic-agents-antibacterials.html" class="nav-button">
                        <span class="nav-icon">‚Üê</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 27%;"></div> <!-- Set percentage dynamically -->
                        </div>
                       <span class="progress-text">Lecture 3 of 11</span> <!-- Update text -->
                    </div>
                    <a href="pharmacology-chemotherapeutic-agents-antiparasitics.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">‚Üí</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">Chemotherapeutic Agents: Antimycobacterials, Antifungals, and Antivirals</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">

                <!-- START: antimycobacterial-agents -->
                <section id="antimycobacterial-agents" class="content-section" aria-labelledby="section-heading-antimycobacterial">
                    <h2 id="section-heading-antimycobacterial" class="section-heading">
                         <span class="heading-icon">ü¶†</span>
                        <span class="heading-text">5. ANTIMYCOBACTERIAL AGENTS</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading" id="drugs-for-tb">a) Drugs used in tuberculosis</h3>
                        <p>Mycobacterium tuberculosis is difficult to treat due to:</p>
                        <ul>
                            <li>It has a characteristic lipid-rich cell wall (made of mycolic acid)</li>
                            <li>Long duration of therapy</li>
                            <li>Able to survive in macrophage hence greater inaccessibility to drugs</li>
                            <li>Very slow growing</li>
                            <li>Dormant states are very resistant to chemicals</li>
                            <li>Emergence of multi-drug resistant strains.</li>
                            <li>The side effects associated with some drugs interfere with compliance.</li>
                            <li>The association of TB with HIV/AIDS further weakens the immunity</li>
                            <li>The nature of transmission: inhalation of droplets.</li>
                        </ul>

                        <h4 class="subsubsection-heading" id="first-line-anti-tb">1st line anti-TB drugs</h4>
                        <h5 class="subsubsection-heading">1. Isoniazid (INH)</h5>
                        <p>Bacteriocidal for dividing bacilli, Bacteriostatic for semidormant bacilli.</p>
                        <p><strong>Mxn:</strong> inhibits synthesis of mycolic acid. Has a structure similar to pyridoxine (vit B<sub>6</sub>)</p>
                        <p><strong>Administration:</strong> per oral</p>
                        <p><strong>Absorption:</strong> well absorbed</p>
                        <p><strong>Distribution:</strong> to all body tissues and fluids including CSF and enters macrophages</p>
                        <p><strong>Elimination:</strong> Undergoes liver metabolism. $t_{1/2}$ average: 1-3 hrs. Renal excretion of metabolites & INH itself.</p>
                        <p><strong>S/E:</strong></p>
                        <ol>
                            <li>Peripheral neuropathy - most frequent S/E, especially in diabetics, malnutrition, alcoholics: NB. There is need to supplement pyridoxine.</li>
                            <li>Hepatotoxicity - most severe S/E - nausea, vomiting, jaundice, right upper quandrant pain (discontinue the drug).</li>
                            <li>Hypersensitivity reactions - rash, fever.</li>
                            <li>Hematological and GIT disturbance, Anemia</li>
                            <li>CNS toxicity (rare) - memory loss, incoordination, seizures, optic neuritis</li>
                        </ol>
                        <p><strong>Drug interactions:</strong> Inhibits metabolism of anticonvulsants</p>

                        <h5 class="subsubsection-heading">2. RIFAMPICIN (rifampin)</h5>
                        <p>Bacteriocidal (to both intracellular & extracellular bacteria)</p>
                        <p><strong>Mechanism:</strong> Inhibits RNA synthesis and is active especially against semidormant bacilli.</p>
                        <p><strong>Administration:</strong> per oral</p>
                        <p><strong>Absorption:</strong> adequately absorbed</p>
                        <p><strong>Distribution:</strong> wide into most tissues and fluids, into phagocytes, abscesses, inflamed meninges.</p>
                        <p><strong>Elimination:</strong> $t_{1/2}$-4 hrs (but it's a powerful enzyme inducer & induces its own metabolism) -Liver metabolism; most excreted into bile.</p>
                        <p><strong>S/E: minor</strong></p>
                        <ol>
                            <li>GIT irritation</li>
                            <li>Hypersensitivity - fever, flushing, itching, rash, influenza-like syndrome, acute hemolytic anemia</li>
                            <li>Cholestatic jaundice (rise in bilirubin), hepatitis - especially in those with hepatic insufficiency, alcoholics, (NB. Monitor liver function)</li>
                            <li>Renal damage</li>
                            <li>Stains body fluids orange-red (in eyes this may permanently stain contact lenses)</li>
                        </ol>
                        <p><strong>Drug interactions (it is a powerful enzyme inducer):</strong> Anticoagulants, anticonvulsants, oral hypoglycemics, contraceptives, protease inhibitors, cyclosporine, dapsone, chloramphenicol, ketoconazole.</p>
                        <p><strong>Uses:</strong></p>
                        <ol>
                            <li>Mycobacterial prophylaxis - those sensitive to INH, or at risk of TB resistant to INH</li>
                            <li>Atypical mycobacteria</li>
                            <li>Meninigoccal elimination in carriers</li>
                            <li>Menigitis due to resistant pneumococci (co-administer with a ceftriaxone) bones, prosthetic valve endocarditis.</li>
                        </ol>

                        <h5 class="subsubsection-heading">3. PYRAZINAMIDE</h5>
                        <p>Bacteriocidal</p>
                        <p><strong>Mxn:</strong> unknown. It's a prodrug converted to active form pyrazinoic acid by pyrazinamidase. Active in acidic environment (e.g. lysosomes), active especially on semidormant bacteria</p>
                        <p><strong>Administration:</strong> per oral & well absorbed</p>
                        <p><strong>Distribution:</strong> wide including CSF</p>
                        <p><strong>Elimination:</strong> $t_{1/2}$-9 hrs. undergoes extensive metabolism in liver.</p>
                        <p><strong>S/E:</strong> Hepatotoxicity, GIT irritation, Anemia, Urticaria. Hyperuricemia and arthralgia (a NSAID treatment is sufficient)</p>

                        <h5 class="subsubsection-heading">4. ETHAMBUTOL</h5>
                        <p>Bacteriostatic</p>
                        <p><strong>Mechanism:</strong> inhibits mycobacterial enzyme involved in cell wall synthesis</p>
                        <p><strong>Administration:</strong> per oral & well absorbed</p>
                        <p><strong>Distribution:</strong> achieves effective concentration in most tissues; penetrates only inflamed meninges.</p>
                        <p><strong>Elimination:</strong> $t_{1/2}$-4 hrs. Undergoes renal clearance (NB. Monitor Renal function)</p>
                        <p><strong>S/E:</strong> Optic neuritis -can be unilateral or bilateral leading to decreased visual acuity, red-green color blindness. NB: it is reversible if prompt discontinuation of drug. Examine visual function regularly. Peripheral neuritis(rare)-in the form of numbness, tingling sensation. GIT disturbances.</p>
                        <p><strong>Interaction:</strong> inhibits uric acid excretion (worsens gout).</p>
                        <p><strong>C/I:</strong> optic neuritis</p>

                        <h5 class="subsubsection-heading">5. STREPTOMYCIN</h5>
                        <p>(an aminoglycoside): $2^{\text{nd}}$ line.</p>
                        <p><strong>USES:</strong> Severe tuberculosis (life threatening) - miliary TB (disseminated), tuberculous meningitis, resistant TB.</p>
                        <p><strong>S/E:</strong> see notes on aminoglycosides.</p>
                        <p>Limit treatment duration to 6 months</p>
                        <p><strong>Dose:</strong> 15mg/kg/d (I.M only).</p>

                        <h4 class="subsubsection-heading" id="second-line-anti-tb">$2^{\text{nd}}$ line drugs</h4>
                        <p>They include amikacin, ethionamide, ciprofloxacin, capreomycin, cycloserine e.t.c.</p>
                        <aside class="callout note" role="note">
                            <h4 class="callout-title"><span class="callout-icon">üìù</span> Note</h4>
                            <p>Refer MOH/CDC/JPHIEGO TB RX</p>
                        </aside>

                        <h3 class="subsection-heading" id="drugs-for-leprosy">b). DRUGS USED IN LEPROSY (M. leprae)</h3>
                        <p>The two major forms of leprosy are:</p>
                        <ul>
                            <li>Tuberculoid type - with few bacilli</li>
                            <li>Lepromatous type - with numerous bacilli</li>
                        </ul>
                        <h4 class="subsubsection-heading">1. Dapsone</h4>
                        <p><strong>Mechanism:</strong> folic acid synthesis inhibitor</p>
                        <p><strong>Administration:</strong> per oral</p>
                        <p><strong>Absorption:</strong> well absorbed</p>
                        <p><strong>Distribution:</strong> wide into tissues and fluids</p>
                        <p><strong>Elimination:</strong> $t_{1/2}$-1-2 days (average = 27hrs) - retained in organs e.g. liver, kidney, skin, muscle. Biliary excretion and renal excretion</p>
                        <p><strong>S/E:</strong> Hemolysis (mild). GIT disturbance (anorexia, nausea, vomiting). Hypersensitivity - Allergic dermatitis, fever, erythema nodosum leprosum (leproid-like reaction) (administer corticosteroid for the latter). Neuropathy</p>

                        <h4 class="subsubsection-heading">2. CLOFAZIMINE</h4>
                        <p><strong>Mechanism:</strong> interferes with DNA functioning</p>
                        <p><strong>Administration:</strong> per oral</p>
                        <p><strong>Absorption:</strong> variable</p>
                        <p><strong>Elimination:</strong> biliary excretion. $t_{1/2}$ - long (2 months) due to storage in tissues such as reticuloendothelial system (macrophages) and skin from where it is slowly released.</p>
                        <p><strong>S/E:</strong> Red-brown discoloration of skin and urine (wounds - blue-black color). GIT disturbance. CNS disturbance - headache</p>

                        <h4 class="subsubsection-heading">3. RIFAMPICIN</h4>
                        <p><strong>Uses:</strong> In combination with dapsone to reduce resistance</p>
                        <p><strong>Dose:</strong> 600 mg OD (P.O)</p>
                        <p>Other minor drugs- Ethionamide & Thalidomide</p>

                        <h4 class="subsubsection-heading">Treatment Regimens for leprosy</h4>
                        <ul>
                            <li><strong>Tuberculoid leprosy</strong> - Dapsone & rifampicin for 6 months</li>
                            <li><strong>Lepromatous leprosy</strong> - dapsone, rifampicin, & clofazimine for $\ge$ 2 years (follow up for 4-6 yrs)</li>
                        </ul>
                    </div>
                </section>
                <!-- END: antimycobacterial-agents -->

                <!-- START: antifungal-agents -->
                <section id="antifungal-agents" class="content-section" aria-labelledby="section-heading-antifungal">
                    <h2 id="section-heading-antifungal" class="section-heading">
                         <span class="heading-icon">üçÑ</span>
                        <span class="heading-text">ANTIFUNGALS</span>
                    </h2>
                    <div class="content-card">
                        <p>Fungal infections: Largely grouped into : Superficial (mucocutaneous, subcutaneous) and Systemic infections.</p>
                        <h3 class="subsection-heading">1. AMPHOTERICIN B</h3>
                        <p>Fungicidal, broad spectrum</p>
                        <p><strong>MOA:</strong> Binds ergosterol & form pores leading to leakage of ions and macromolecules & cell death</p>
                        <p><strong>Administered:</strong> Parenteral for systemic effect.</p>
                        <p><strong>Distribution:</strong> widely into body tissues and fluids. Enters CSF if inflamed meninges and when coadministered with Flucytosine.</p>
                        <p><strong>Elimination:</strong> $t_{1/2}$-15 days (persists in the body for several weeks after cessation of treatment). Largely metabolized, Some renal excretion</p>
                        <p><strong>S/E:</strong></p>
                        <ol>
                            <li>Nephrotoxic: very common</li>
                            <li>Hepatic dysfunction</li>
                            <li>Thrombocytopenia</li>
                            <li>Anaphylactic reactions</li>
                            <li>Infusion related effects: -Fever, chills, nausea & vomiting, headache, muscle spasm and joint pain, hypotension, Local thrombophlebitis</li>
                        </ol>
                        <p><strong>D/I:</strong> synergistic with flucytosine (probably by increasing permeability)</p>
                        <p><strong>Uses:</strong></p>
                        <p>Systemic use:</p>
                        <ol>
                            <li>(DOC) for serious systemic mycotic infections e.g. cryptococcal meningitis, fungal pneumonia, sepsis due to fungi.</li>
                        </ol>
                        <p>Local use:</p>
                        <ol>
                            <li>Mycotic infections of - GIT, eye, fungal arthritis, mycotic infections of the bladder (through bladder irrigation)</li>
                        </ol>
                        <p><strong>Contraindication(C/I):</strong> Renal failure.</p>

                        <h3 class="subsection-heading">2. AZOLES</h3>
                        <p><strong>Mechanism:</strong> Inhibition of synthesis of ergosterol</p>
                        <p><strong>Spectrum:</strong> Broad</p>
                        <p>Examples: ketoconazole, fluconazole, itraconazole</p>
                        <h4 class="subsubsection-heading">A) KETOCONAZOLE:</h4>
                        <p><strong>Administration:</strong> per oral</p>
                        <p><strong>Absorption:</strong> best on acidic medium and with food. Absorption reduced by: antacids, proton pump inhibitors, $H_2$- blockers which reduce gastric pH</p>
                        <p><strong>Distribution:</strong> has poor CSF penetration</p>
                        <p><strong>Elimination:</strong> hepatic elimination</p>
                        <p><strong>S/E:</strong></p>
                        <ol>
                            <li>Endocrine effects: gynecomastia, menstrual irregularities, infertility, alopecia, decreased libido (inhibit steroid hormone synthesis).</li>
                            <li>GIT irritation</li>
                        </ol>
                        <p><strong>D/I:</strong> Rifampicin</p>
                        <p><strong>Uses:</strong> Mucocutaneous candidiasis</p>
                        <p><strong>Dose:</strong> 200-400mg OD (P.O).</p>
                        <p><strong>C/I:</strong> pregnancy and lactation, hepatic disorders.</p>

                        <h4 class="subsubsection-heading">B) ITRACONAZOLE (most potent of the azoles)</h4>
                        <p><strong>Administration:</strong> oral & parenteral (I.V)</p>
                        <p>Has features like ketoconazole.</p>
                        <p><strong>S/E (dose dependent):</strong> GIT irritation</p>
                        <p><strong>Uses:</strong></p>
                        <ol>
                            <li>Aspergillosis (the main drug with significant activity)</li>
                            <li>DOC for Dermatophytoses, Onychomycosis, Histoplasma, Blastomyces, Sporothrix.</li>
                        </ol>
                        <p><strong>Dose:</strong> 100-400mg/d (I.V, P.O)</p>

                        <h4 class="subsubsection-heading">C) FLUCONAZOLE</h4>
                        <p><strong>Administration:</strong> oral & parenteral</p>
                        <p><strong>Absorption:</strong> good</p>
                        <p><strong>Distribution:</strong> good and can enter into CSF</p>
                        <p><strong>S/E:</strong> Least effect on GIT irritation</p>
                        <p><strong>USES:</strong></p>
                        <ol>
                            <li>DOC treatment of cryptococcal meningitis</li>
                            <li>DOC prophylaxis of cryptococcal meningitis</li>
                            <li>Candidemia</li>
                            <li>Mucocutaneus candidiasis</li>
                        </ol>
                        <p><strong>Dose:</strong> 100-800mg/d in divided doses.</p>

                        <h3 class="subsection-heading">3. FLUCYTOSINE</h3>
                        <p><strong>Mechanism:</strong> inhibit DNA and RNA synthesis.</p>
                        <p><strong>Administration:</strong> oral & well absorbed.</p>
                        <p><strong>Distribution:</strong> into all body tissues and fluids including CSF</p>
                        <p><strong>Elimination:</strong> $t_{1/2}$-4hrs; Renal excretion.</p>
                        <p><strong>S/E:</strong></p>
                        <ol>
                            <li>Bone marrow depression: pancytopenia</li>
                            <li>Alopecia</li>
                            <li>Liver damage</li>
                            <li>Toxic enterocolitis (GIT disturbance)</li>
                        </ol>
                        <p><strong>D/I:</strong> Synergistic with amphotericin B and azoles</p>
                        <p><strong>Uses:</strong> (always combined with others to prevent resistance)</p>
                        <ul>
                            <li>Cryptococcal meningitis</li>
                            <li>Some dermatophytic infection</li>
                        </ul>

                        <h3 class="subsection-heading">4. GRISEOFULVIN</h3>
                        <p>Deposited in newly forming skin,nail, hair where it binds to keratin, protecting from new infections.</p>
                        <p><strong>Absorption:</strong> improved with fatty foods.</p>
                        <p><strong>Use:</strong> treatment of dermatophytosis</p>
                        <p><strong>Dose:</strong> 1g/d. (may require therapy for months)</p>
                        <p><strong>S/E:</strong> Allergic reactions, hepatitis</p>

                        <h3 class="subsection-heading">TOPICAL ANTIFUNGALS</h3>
                        <h4 class="subsubsection-heading">1. NYSTATIN</h4>
                        <p><strong>Mechanism:</strong> binds ergosterol causing pore formation & cell wall disruption.</p>
                        <p><strong>Administration:</strong> topical or local only (it is too toxic for systemic use)</p>
                        <p><strong>Absorption:</strong> very poor.</p>
                        <p><strong>Uses:</strong> Candida infections - oropharynx, GIT, vagina, cutaneous.</p>

                        <h4 class="subsubsection-heading">2. TOPICAL AZOLES</h4>
                        <p>e.g. Clotrimazole and miconazole</p>
                        <p><strong>Uses:</strong> Vulvovaginal candidiasis, oral thrush, dermatophytic infections (-tinea corporis, tinea pedis, and tinea cruris).</p>
                        <p><strong>S/E:</strong> very rare</p>
                    </div>
                </section>
                <!-- END: antifungal-agents -->

                <!-- START: antiviral-agents-intro -->
                <section id="antiviral-agents-intro" class="content-section" aria-labelledby="section-heading-antiviral-intro">
                    <h2 id="section-heading-antiviral-intro" class="section-heading">
                         <span class="heading-icon">üî¨</span>
                        <span class="heading-text">Viruses and Their Characteristics</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Does not have components of a cell</li>
                            <li>Unable to replicate outside of a living host cell</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_06_04_448780967d4f74d330c7g-27-1.jpg" alt="Diagram of a virus infecting a bacterium, illustrating a typical bacteriophage structure." class="content-image">
                            <figcaption>A virus infecting a bacterium.</figcaption>
                        </figure>
                        <p>Most viruses are spread through the following routes:</p>
                        <ul>
                            <li>Direct contact</li>
                            <li>Ingestion of contaminated food and water</li>
                            <li>Inhalation of airborne particles</li>
                            <li>Exposure to contaminated body fluids/equipment</li>
                        </ul>
                        <p>Parts of a virus particle, virion</p>
                        <ul>
                            <li>Nucleic acid consisting of either DNA or RNA, not both</li>
                            <li>Capsid (protein shell) that surrounds and protects the nucleic acid</li>
                            <li>Naked virus</li>
                            <li>Virus without an envelope covering the capsid</li>
                        </ul>
                    </div>
                </section>
                <!-- END: antiviral-agents-intro -->

                <!-- START: viral-infection-stages -->
                <section id="viral-infection-stages" class="content-section" aria-labelledby="section-heading-viral-stages">
                    <h2 id="section-heading-viral-stages" class="section-heading">
                         <span class="heading-icon">üîÑ</span>
                        <span class="heading-text">Stages of Viral Infection</span>
                    </h2>
                    <div class="content-card">
                        <ol>
                            <li>Virus attaches to a cell receptor.</li>
                            <li>Cell membrane indents and closes around the virus, thus the virus penetrates the cell.</li>
                            <li>Virus escapes into cytoplasm.</li>
                            <li>Virus uncoats, shedding its covering and releasing DNA or RNA into cell nucleus.</li>
                        </ol>
                        <p>Viruses are intracellular parasites.</p>
                    </div>
                </section>
                <!-- END: viral-infection-stages -->

                <!-- START: hiv-lifecycle-arvs -->
                <section id="hiv-lifecycle-arvs" class="content-section" aria-labelledby="section-heading-hiv">
                    <h2 id="section-heading-hiv" class="section-heading">
                         <span class="heading-icon">üß¨</span>
                        <span class="heading-text">HIV Lifecycle and Antiretrovirals (ARVs)</span>
                    </h2>
                    <div class="content-card">
                        <p>HIV belongs to a group of viruses known as retroviruses, which carry their genetic material in the form of ribonucleic acid (RNA) rather than deoxyribonucleic acid (DNA).</p>
                        <figure>
                             <img src="../assets/images/2025_06_04_5c11892027ae24547522g-05-1.jpg" alt="Detailed diagram illustrating the HIV replication cycle within a CD4 T-cell, showing attachment, uncoating, DNA synthesis, integration, transcription, translation, assembly, and budding." class="content-image">
                        </figure>
                        <ol>
                            <li><strong>Attachment.</strong> In this first step, the GP120 and GP41 glycoproteins of HIV bind with the host's uninfected CD4 receptor and chemokine co-receptors which results in fusion of HIV with the CD4 T-cell membrane.</li>
                            <li><strong>Uncoating.</strong> The contents of HIV's viral core (two single strands of viral RNA and three viral enzymes: reverse transcriptase, integrase, and protease) are emptied into the CD4 T-cell.</li>
                            <li><strong>DNA synthesis.</strong> HIV changes its genetic material from RNA to DNA through action of reverse transcriptase, resulting in double-stranded DNA that carries instruction for viral replication.</li>
                            <li><strong>Integration.</strong> New viral DNA enters the nucleus of the CD4 T cell and through action of integrase is blended with the DNA of the CD4 T cell, resulting in permanent, lifelong infection.
                                <p>NB-Prior to this step, the uninfected person has been only exposed to, not infected with, HIV. With this step, HIV infection is permanent.</p>
                            </li>
                            <li><strong>Transcription.</strong> When the CD4 T cell is activated, the double-stranded DNA forms single-stranded messenger RNA (mRNA), which builds new viruses.</li>
                            <li><strong>Translation.</strong> The mRNA creates chains of new proteins and enzymes (polyproteins) that contain the components needed in the construction of new viruses.</li>
                            <li>Polyprotein chain into the individual proteins that make up the new virus. (Note: PDF content was slightly abrupt here, likely referring to Protease action)</li>
                            <li><strong>Budding.</strong> New proteins and viral RNA migrate to the membrane of the infected CD4 T cell, exit from the cell, and start the process all over.</li>
                        </ol>

                        <h3 class="subsection-heading">ANTIRETROVIRALS (ARVs)</h3>
                        <p><strong>Uses:</strong> HIV infection</p>
                        <ol>
                            <li><strong>Nucleoside reverse transcriptase inhibitors (NRTIs):</strong> Inhibit the action of reverse transcriptase to prevent the formation of viral RNA from proviral DNA. Cause a decrease in the amount of virus in the body and subsequent spread to other healthy cells.</li>
                            <li><strong>Non-nucleoside reverse transcriptase inhibitors (NNRTIs):</strong> Inhibit the action of HIV reverse transcriptase but at a different site on the enzyme than the site targeted by NRTIs</li>
                            <li><strong>Protease inhibitors:</strong> Inhibit the protease enzyme, which typically cleaves certain HIV protein precursors that are necessary for the replication of new infectious virons</li>
                            <li><strong>Entry inhibitors - fusion inhibitors (Enfuvirtide):</strong> Prevents AIDS virus from entering the immune cells.</li>
                        </ol>

                        <h4 class="subsubsection-heading">Classes of Anti Retro Virals</h4>
                        <ul>
                            <li>Reverse transcriptase (RT) inhibitors
                                <ul>
                                    <li>Nucleoside RT inhibitors (NRTI)</li>
                                    <li>Non-nucleoside RT inhibitors (NNRTI)</li>
                                    <li>Nucleotide RT inhibitors (NtRTI)</li>
                                </ul>
                            </li>
                            <li>Protease inhibitors (PI)</li>
                            <li>Entry Inhibitors
                                <ul>
                                    <li>Attachment inhibitors</li>
                                    <li>Chemokine receptor antagonists</li>
                                    <li>Fusion inhibitors</li>
                                </ul>
                            </li>
                            <li>Integrase inhibitors</li>
                        </ul>

                        <h4 class="subsubsection-heading">1. Nucleoside reverse transcriptase inhibitors (NRTIs)</h4>
                        <ul>
                            <li>a) Zidovudine (azidothymidine, AZT)</li>
                            <li>b) Stavudine (d4T)</li>
                            <li>c) Didanosine (ddI)</li>
                            <li>d) Lamivudine (3TC)</li>
                            <li>e) Zalcitabine (ddC)</li>
                            <li>f) Abacavir (ABC)</li>
                            <li>g) Combivir (AZT + 3TC)</li>
                            <li>h) Trizivir (AZT + 3TC + abacavir)</li>
                        </ul>
                        <p><strong>General features of NRTIs</strong></p>
                        <p><strong>Adm:</strong> oral</p>
                        <p><strong>Abs:</strong> adequate. Absorption of ddC is interfered with by food, antacids, metoclopramide.</p>
                        <p><strong>Distribution:</strong> wide including CSF, brain</p>
                        <p><strong>Elimination:</strong> most are renally excreted.</p>
                        <p><strong>S/E - general for NRTIs:</strong></p>
                        <ol>
                            <li>Mitochondrial toxicities (especially d4T, ddI in pregnancy)</li>
                            <li>Bone marrow depression (anemia, neutropenia especially with ZDV, d4T)</li>
                            <li>Hepatotoxicity (d4T, ABC)</li>
                            <li>Pancreatitis (ddI, ddC, d4T)</li>
                            <li>Hypersensitivity (ABC, most serious toxicity)</li>
                            <li>Lipodystrophy (ZDV, d4T)</li>
                            <li>Lactic acidosis (ZDV, d4T, ddI)</li>
                        </ol>

                        <h4 class="subsubsection-heading">2. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)</h4>
                        <p>They include: Nevirapine (NVP), efavirenz (EFV), delavirdine (DLV).</p>
                        <p><strong>General Pharmacokinetics</strong></p>
                        <p><strong>Administration:</strong> oral</p>
                        <p><strong>Absorption:</strong> good.</p>
                        <p><strong>Distribution:</strong> wide including CSF. Nevirapine - crosses the placenta. Efavirenz - protein bound.</p>
                        <p><strong>Elimination:</strong> metabolized in the liver. Efavirenz has a long $t_{1/2}$. Nevirapine - inducer of cyp P450 enzymes. Efavirenz - mainly inducer of cyp 450 enzymes. Delavirdine - inhibitor of cyp 450 enzymes.</p>
                        <p>NB: These drugs have a lot of drug interactions.</p>
                        <p><strong>S/E in general:</strong></p>
                        <ol>
                            <li>Hypersensitivity reactions : Steven-Johnsons syndrome (NVP, DLV, EFV)</li>
                            <li>CNS toxicity: headache, dizziness, drowsiness, confusion, amnesia, delusions, depression, euphoria, agitation (EFV)</li>
                            <li>Hepatitis</li>
                            <li>GIT irritation - nausea, vomiting, diarrhea</li>
                        </ol>
                        <p>NB: EFV & DLV are best if avoided in pregnancy.</p>

                        <h4 class="subsubsection-heading">3. PROTEASE INHIBITORS (PIs)</h4>
                        <p><strong>General properties of protease inhibitors</strong></p>
                        <p><strong>Adm:</strong> oral</p>
                        <p><strong>Abs:</strong> Saquinavir (take with fatty food to enhance absorption). Indinavir - take on empty stomach for maximum absorption. Ritonavir - absorption increased with food. Nelfinavir - absorption increased with food. Amprenavir - rapid absorption (with or without food, high fat food decreases absorption).</p>
                        <p><strong>Distribution:</strong> saquinavir -wide but does not enter CSF. Indinavir - achieves effective concentration in the CSF.</p>
                        <p><strong>Elimination:</strong> all excreted via bile. All are inhibitors of cyp P450 enzymes hence they increase concentration of drugs e.g. benzodiazepines</p>
                        <p><strong>General S/E of protease inhibitors:</strong></p>
                        <ol>
                            <li>GIT irritation - including dyspepsia.</li>
                            <li>Lipodystrophy & insulin resistance, causing altered body fat distribution - (buffalo hump, truncal obesity, facial and peripheral atrophy) and hyperlipidemia</li>
                            <li>Nephrolithiasis</li>
                            <li>Liver damage (raised liver enzymes) & hyperbilirubinemia</li>
                            <li>Increased spontaneous bleeding in hemophiliacs</li>
                            <li>Paresthesia (especially ritonavir)</li>
                        </ol>

                        <h4 class="subsubsection-heading">Nucleotide Reverse Transcriptase Inhibitors (NtRTIs)</h4>
                        <ul>
                            <li>Inhibit the activity of HIV-1 reverse transcriptase by competing with natural nucleic acid substrates</li>
                            <li>Cause termination of chain formation after incorporating in viral nucleic acid</li>
                        </ul>
                        <p>Example: tenofovir (Viread)</p>

                        <h4 class="subsubsection-heading">HIV TREATMENT</h4>
                        <p>Primary goal of HIV treatment is:</p>
                        <ul>
                            <li>Prevention of complications of HIV</li>
                            <li>Prolong survival</li>
                        </ul>
                        <p>HAART - initial triple combination</p>
                        <p>2 NRTIs +1 PI or NNRTI (e.g. NVP or EFA, lamivudine, stavudine)</p>
                        <p>Treatment aims to achieve</p>
                        <ul>
                            <li>Potency</li>
                            <li>Adherence (doses per day) & tolerability (S/E short and long term)</li>
                            <li>Minimal drug-drug interactions</li>
                        </ul>
                    </div>
                </section>
                <!-- END: hiv-lifecycle-arvs -->

                <!-- START: other-antivirals -->
                <section id="other-antivirals" class="content-section" aria-labelledby="section-heading-other-antivirals">
                    <h2 id="section-heading-other-antivirals" class="section-heading">
                         <span class="heading-icon">üíä</span>
                        <span class="heading-text">OTHER ANTI-VIRAL AGENTS</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">1. ANTI-INFLUENZA AGENTS - Amantadine and rimantadine</h3>
                        <p><strong>Administartion:</strong> oral</p>
                        <p><strong>Absorption:</strong> good</p>
                        <p><strong>Distribution:</strong> wide (only amantadine enters into CSF)</p>
                        <p><strong>S/E:</strong> CNS disturbance (especially with amantadine). Teratogenic and embryotoxic - avoid in pregnancy</p>
                        <p><strong>Uses:</strong> influenza A in patients allergic to the vaccine and in epidemics.</p>

                        <h3 class="subsection-heading">2. DNA POLYMERASE INHIBITORS (inhibitors of transcription)</h3>
                        <p>a) Acyclovir</p>
                        <p>b) Valacyclovir -converted to acyclovir</p>
                        <p>c) Penciclovir - (topical)</p>
                        <p>d) Famciclovir - oral - converted to penciclovir by first pass metabolism</p>
                        <p>e) Ganciclovir -oral and parenteral</p>
                        <p><strong>Spectrum:</strong> Herpesvirus and cytomegalovirus (CMV), varicella zoster virus (VZV)</p>
                        <p><strong>S/E:</strong> GIT irritation, Headache. Renal & CNS toxicity with high conc. or rapid infusion of acyclovir -(especially in those with dehydration). Thrombotic microangiopathies and hemolyticuremic syndrome especially for Valacyclovir with high doses. CNS effects (confusion, hallucinations) with valacyclovir</p>
                        <p><strong>Uses: Acyclovir & Valacyclovir, Famciclovir & penciclovir</strong></p>
                        <ul>
                            <li>Herpes simplex infections - mucocutaneous and genital</li>
                            <li>Herpes simplex encephalitis (DOC, IV)</li>
                            <li>Varicella zoster virus infection.</li>
                        </ul>
                        <p><strong>Uses: Ganciclovir (intraocular implant or direct intravitreal injection)</strong></p>
                        <ol>
                            <li>CMV infections e.g retinitis.</li>
                            <li>Before organ transplantation to reduce risk of CMV manifestations</li>
                        </ol>
                        <p><strong>S/E Ganciclovir:</strong> Intraocular administration can lead to retinal detachment, hemorrhage. Bone marrow suppression. CNS toxicity: headache, seizures. Carcinogenic, embryotoxic, teratogenic.</p>
                    </div>
                </section>
                <!-- END: other-antivirals -->

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="pharmacology-chemotherapeutic-agents-antibacterials.html" class="nav-button">
                        <span class="nav-icon">‚Üê</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 27%;"></div> <!-- Set percentage dynamically -->
                        </div>
                       <span class="progress-text">Lecture 3 of 11</span> <!-- Update text -->
                    </div>
                    <a href="pharmacology-chemotherapeutic-agents-antiparasitics.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">‚Üí</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script> <!-- Basic JS for disabled links etc. -->
</body>
</html>